Working… Menu

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00490009
Recruitment Status : Completed
First Posted : June 22, 2007
Results First Posted : February 28, 2017
Last Update Posted : March 30, 2017
Corixa Corporation
Information provided by (Responsible Party):
Susan Knox, Stanford University

Brief Summary:
The purpose of this study is to obtain safety and efficacy data using Bexxar in patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL).

Condition or disease Intervention/treatment Phase
Lymphoma Drug: Bexxar Drug: Acetaminophen Drug: Diphenhydramine Drug: Potassium Iodide (KI) Phase 2

Detailed Description:

There is a lack of efficacious treatment options for patients with relapsed/refractory diffuse large cell Non-Hodgkin's lymphoma (DLCL) who are not appropriate candidates for stem cell transplantation. DLCL is a relatively radiosensitive disease and patients with DLCL have been reported to respond to anti-CD20 monoclonal antibody (MAB) therapy. Therefore, radioimmunotherapy targeting CD20 is a rational and promising therapeutic approach for this patient population.

This study evaluated if Bexxar is safe and efficacious for diffuse large cell Non-Hodgkin's lymphoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)
Study Start Date : September 2004
Actual Primary Completion Date : April 2010
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma Potassium

Arm Intervention/treatment
Experimental: Bexxar + Total Body Irradiation (TBI)
Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
Drug: Bexxar

Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.

Bexxar will be administered to provide the following patient-specific radiotherapy:

  • Platelet count of 150,000/mm³ = 75 cGy
  • Platelet count ≥ 100,000/mm³ but < 150,000/mm³ = 65 cGy
Other Names:
  • Tositumomab
  • iodine-131 tositumomab
  • I-131 tositumomab

Drug: Acetaminophen
As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
Other Name: Tylenol

Drug: Diphenhydramine
As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
Other Name: Benadryl

Drug: Potassium Iodide (KI)
Administered to prevent thyroid blockage 130 mg orally 3 times a day,
Other Names:
  • Saturated solution potassium iodine (SSKI)
  • Lugol's solution

Primary Outcome Measures :
  1. Clinical Response Rate [ Time Frame: 6 years ]
    Clinical response rate for all participants, reported as the sum of the numbers of patients achieving complete response (CR, complete disappearance of all lesions); functional CR (fCR, minimal residual disease but clear of disease by positron emission tomography (PET)-scan); or partial response (PR, ≥ decrease in size of lesions and negative for active disease by PET-scan). Progressive disease (PD, advancing cancer) or stable disease (not CR, fCR, or PD) not included as Clinical Response.

Secondary Outcome Measures :
  1. Time to Progression (TTP) [ Time Frame: 1.5 months; 3 months; 6 months; or Not Progressed ]
    Time of disease progression reported as the number of subjects experiencing disease progression at the time point of progression.

  2. Overall Survival (OS) Rate [ Time Frame: 6 years ]
    Overall survival reported as the percentage of participants (less lost-to-follow-up) surviving at 6 years.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically-confirmed, diffuse large cell lymphoma (DLCL), CD20+ B-cell non-Hodgkin lymphoma (NHL) who have relapsed after chemotherapy or are chemotherapy resistant, without prior history of low grade NHL. The patient must have failed at least one chemotherapy regimen containing an anthracycline or equivalent chemotherapeutic agent.
  • No anticancer treatment for three weeks prior to the treatment dose of Bexxar (6 weeks if Rituximab, nitrosourea or Mitomycin C)
  • Fully recovered from all toxicities associated with prior surgery, radiation, chemotherapy or immunotherapy
  • An Institutional Review Board (IRB)-approved signed informed consent
  • Age 19 years or older
  • Prestudy Karnofsky Performance Status of ≥ 70%
  • Absolute neutrophil count (ANC) ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hct > 30%
  • Hgb > 9.0 gm%
  • Bilirubin ≤ 2.0
  • Creatinine ≤ 2.0
  • Bone marrow involvement with lymphoma less than 25% (bilateral bone marrow) within 6 weeks of enrollment
  • Acceptable birth control method for men and women
  • Female patients who are not pregnant
  • Not lactating

Exclusion Criteria:

  • Prior myeloablative therapies with bone marrow transplantation or peripheral stem cell rescue
  • Platelet count < 100,000/mm³
  • Hypocellular bone marrow (≤ 15% cellularity)
  • Marked reduction in bone marrow precursors of one or more cell lines
  • History of failed stem cell collection
  • Prior treatment with Fludarabine
  • Prior radioimmunotherapy
  • Presence of central nervous system (CNS) lymphoma
  • Patients with known HIV or AIDS-related lymphoma
  • Patients with evidence of myelodysplasia on bone marrow biopsy
  • Patients who have received prior external beam radiation therapy to more than 25% of active bone marrow
  • Patients who have received filgrastim or sargramostim therapy within 3 weeks prior to treatment
  • Pregnant
  • Lactating
  • Presence of human anti-mouse antibody (HAMA) reactivity in patients with prior exposure to murine antibodies or proteins
  • Serious nonmalignant disease or infection, which, in the opinion of the investigator, would compromise other protocol objectives
  • Another primary malignancy (other than squamous cell and basal cell carcinoma of the skin, in situ carcinoma of the cervix, or treated prostate cancer with stable prostate specific antigen levels) for which the patients has not been disease-free for at least 3 years
  • Major surgery, other than diagnostic surgery, within 4 weeks
  • Patients with pleural effusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00490009

Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Susan Knox
Corixa Corporation
Layout table for investigator information
Principal Investigator: Susan J Knox Stanford University

Layout table for additonal information
Responsible Party: Susan Knox, Associate Professor, Stanford University Identifier: NCT00490009     History of Changes
Other Study ID Numbers: IRB-10275
LYMNHL0019 ( Other Identifier: OnCore )
30978 ( Other Identifier: Stanford SPO )
First Posted: June 22, 2007    Key Record Dates
Results First Posted: February 28, 2017
Last Update Posted: March 30, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Iodine-131 anti-B1 antibody
Pharmaceutical Solutions
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Growth Substances
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Anesthetics, Local